Compare ADTN & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | ANNX |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 812.7M |
| IPO Year | 1996 | 2020 |
| Metric | ADTN | ANNX |
|---|---|---|
| Price | $16.63 | $5.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $15.50 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 2.7M | 2.1M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,083,807,000.00 | N/A |
| Revenue This Year | $11.09 | N/A |
| Revenue Next Year | $8.47 | $16,320.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.46 | N/A |
| 52 Week Low | $7.11 | $1.85 |
| 52 Week High | $19.98 | $7.18 |
| Indicator | ADTN | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 48.41 |
| Support Level | $8.45 | $4.80 |
| Resistance Level | $18.34 | $5.61 |
| Average True Range (ATR) | 1.14 | 0.28 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 43.03 | 55.96 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.